Middle East Respiratory Syndrome (MERS)-Pipeline Review, H2 2016

Middle East Respiratory Syndrome (MERS)-Pipeline Review, H2 2016


  • Products Id :- GMDHC8898IDB
  • |
  • Pages: 59
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Middle East Respiratory Syndrome (MERS)-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Middle East Respiratory Syndrome-Pipeline Review, H2 2016, provides an overview of the Middle East Respiratory Syndrome (Infectious Disease) pipeline landscape.

Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS?CoV). Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Middle East Respiratory Syndrome-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Middle East Respiratory Syndrome (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 2, 9 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Middle East Respiratory Syndrome (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Middle East Respiratory Syndrome (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Middle East Respiratory Syndrome (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Middle East Respiratory Syndrome (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Middle East Respiratory Syndrome (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Middle East Respiratory Syndrome (Infectious Disease)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Middle East Respiratory Syndrome (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Middle East Respiratory Syndrome (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Middle East Respiratory Syndrome (MERS) Overview 7

Therapeutics Development 8

Pipeline Products for Middle East Respiratory Syndrome (MERS)-Overview 8

Pipeline Products for Middle East Respiratory Syndrome (MERS)-Comparative Analysis 9

Middle East Respiratory Syndrome (MERS)-Therapeutics under Development by Companies 10

Middle East Respiratory Syndrome (MERS)-Therapeutics under Investigation by Universities/Institutes 11

Middle East Respiratory Syndrome (MERS)-Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Middle East Respiratory Syndrome (MERS)-Products under Development by Companies 14

Middle East Respiratory Syndrome (MERS)-Products under Investigation by Universities/Institutes 15

Middle East Respiratory Syndrome (MERS)-Companies Involved in Therapeutics Development 16

Atriva Therapeutics GmbH 16

Autoimmune Technologies LLC 17

Humabs BioMed SA 18

Inovio Pharmaceuticals Inc 19

Nanotherapeutics Inc 20

Novavax Inc 21

Phelix Therapeutics LLC 22

Planet Biotechnology Inc 23

Regeneron Pharmaceuticals Inc 24

Romark Laboratories LC 25

Middle East Respiratory Syndrome (MERS)-Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Combination Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

3B-11-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

ATR-006-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

BNSP-333S1-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

CSW-1-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Drugs to Inhibit Cathepsin L for Coronaviridae Infections-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

FBR-001-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

INO-4500-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

LCA-60-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Middle East respiratory syndrome coronavirus vaccine-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Middle East respiratory syndrome coronavirus vaccine-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Middle East respiratory syndrome vaccine-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Middle East respiratory syndrome vaccine-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

nitazoxanide-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

REGN-3048-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

REGN-3051-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

SAB-301-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Middle East Respiratory Syndrome (MERS)-Product Development Milestones 55

Featured News & Press Releases 55

Dec 06, 2016: Inovio MERS Vaccine Development to be Expanded with Funding from International Vaccine Institute 55

Aug 24, 2016: SAB Biotherapeutics Announces Contract with BARDA to Advance First MERS Treatment 55

Aug 11, 2016: Phase I Clinical Trials Underway for First MERS Treatment 56

Appendix 58

Methodology 58

Coverage 58

Secondary Research 58

Primary Research 58

Expert Panel Validation 58

Contact Us 58

Disclaimer 59

List of Figures

Number of Products under Development for Middle East Respiratory Syndrome (MERS), H2 2016 8

Number of Products under Development for Middle East Respiratory Syndrome (MERS)-Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 26

Number of Products by Targets, H2 2016 28

Number of Products by Stage and Targets, H2 2016 28

Number of Products by Mechanism of Actions, H2 2016 30

Number of Products by Stage and Mechanism of Actions, H2 2016 30

Number of Products by Routes of Administration, H2 2016 32

Number of Products by Stage and Routes of Administration, H2 2016 32

Number of Products by Molecule Types, H2 2016 34

Number of Products by Stage and Molecule Types, H2 2016 34

List of Tables

Number of Products under Development for Middle East Respiratory Syndrome (MERS), H2 2016 8

Number of Products under Development for Middle East Respiratory Syndrome (MERS)-Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Middle East Respiratory Syndrome (MERS)-Pipeline by Atriva Therapeutics GmbH, H2 2016 16

Middle East Respiratory Syndrome (MERS)-Pipeline by Autoimmune Technologies LLC, H2 2016 17

Middle East Respiratory Syndrome (MERS)-Pipeline by Humabs BioMed SA, H2 2016 18

Middle East Respiratory Syndrome (MERS)-Pipeline by Inovio Pharmaceuticals Inc, H2 2016 19

Middle East Respiratory Syndrome (MERS)-Pipeline by Nanotherapeutics Inc, H2 2016 20

Middle East Respiratory Syndrome (MERS)-Pipeline by Novavax Inc, H2 2016 21

Middle East Respiratory Syndrome (MERS)-Pipeline by Phelix Therapeutics LLC, H2 2016 22

Middle East Respiratory Syndrome (MERS)-Pipeline by Planet Biotechnology Inc, H2 2016 23

Middle East Respiratory Syndrome (MERS)-Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 24

Middle East Respiratory Syndrome (MERS)-Pipeline by Romark Laboratories LC, H2 2016 25

Assessment by Monotherapy Products, H2 2016 26

Assessment by Combination Products, H2 2016 27

Number of Products by Stage and Target, H2 2016 29

Number of Products by Stage and Mechanism of Action, H2 2016 31

Number of Products by Stage and Route of Administration, H2 2016 33

Number of Products by Stage and Molecule Type, H2 2016 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Atriva Therapeutics GmbH, Autoimmune Technologies LLC, Humabs BioMed SA, Inovio Pharmaceuticals Inc, Nanotherapeutics Inc, Novavax Inc, Phelix Therapeutics LLC, Planet Biotechnology Inc, Regeneron Pharmaceuticals Inc, Romark Laboratories LC

Middle East Respiratory Syndrome (MERS) Therapeutic Products under Development, Key Players in Middle East Respiratory Syndrome (MERS) Therapeutics, Middle East Respiratory Syndrome (MERS) Pipeline Overview, Middle East Respiratory Syndrome (MERS) Pipeline, Middle East Respiratory Syndrome (MERS) Pipeline Assessment

select a license

Single User License
USD 2000 INR 129800
Site License
USD 4000 INR 259600
Corporate User License
USD 6000 INR 389400

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com